You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Semaglutide- the active ingredient in 'Wegovy' and 'Ozempic'- may lower dementia risk in people with type 2 diabetes. | Drug ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Novo Nordisk AS and a group of insurers will pay $32 million to end litigation over its $1.8 billion acquisition of ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

Mounjaro offers up to 20% weight loss – but it’s not for everyone. Learn about eligibility, alternatives and why long-term ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...